Symptomtext
Placed in the freezer mistakenly with no reported adverse event; Initial information received on 23-Dec-2021 regarding an unsolicited valid non-serious case received from a consumer/non-hcp. This case involves a patient of unknown demographics who received vaccines TYPHOID VI POLYSACCHARIDE VACCINE [TYPHIM VI] and MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE [MENQUADFI] and placed in the freezer mistakenly with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On an unknown date, the patient received a dose of suspect MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE (with an unknown dose, route, frequency, formulation, strength) lot u6936aa in unknown administration site. On an unknown date, the patient received a dose of suspect TYPHOID VI POLYSACCHARIDE VACCINE (with an unknown dose, route, frequency, formulation, strength) lot 1a671m in unknown administration site. On an unknown date the patient developed a non-serious event "placed in the freezer mistakenly with no reported adverse event" (product storage error) (unknown latency) same day following the administration of MENINGOCOCCAL A-C-Y-W135 (T CONJ) VACCINE and TYPHOID VI POLYSACCHARIDE VACCINE. It was reported" Caller is requesting a temperature excursion for the following: menquadfi and Typhim Vi. Cause: Placed in the freezer mistakenly. Lowest Temp: frozen -5F Time exposed to temp: 15 hours Opened or Unopened products: unopened." Action taken with MENINGOCOCCAL VACCINE (MENQUADFI) and TYPHOID VACCINE (TYPHIM VI) was not applicable. It was not reported if the patient received a corrective treatment for the event (Placed in the freezer mistakenly with no reported adverse event). At time of reporting, the outcome was Unknown for the event placed in the freezer mistakenly with no reported adverse event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.